Overview

As Director, Global Early Asset & Business Development you translate early signals into strategic investment decisions across pre-clinical to Phase 3 and in-licensing. You'll lead forecast development, patient-based models, and commercial diligence, partnering with cross-functional teams to inform gates and portfolio choices. In a risk-aware, AI-enabled environment, you will drive speed, clarity, and rigor to shape a winning respiratory and immunology portfolio.

This role combines science, finance, and strategy to impact patient access and outcomes.

Compensaciones / Beneficios in-person work 3 days per week flexible work arrangements global network and development opportunities

Responsabilidades

Lead early forecasting across epidemiology, adoption, and policy shifts to guide stage-gate decisions and allocation of resources

Build patient-based forecast models integrating primary/secondary data and analog benchmarks for investment cases

Deliver commercial diligence and market models for in-licensing, partnerships, and acquisitions with clear risk-adjusted recommendations

Prepare governance-ready narratives for executive reviews, portfolio prioritization, and opportunity assessments

Advise senior leaders on forecast drivers, model changes, and implications for pipeline and deal strategy

Contribute to disease strategy by informing R&I; direction with insights on unmet need and market evolution





Design and oversee vendor-led qualitative and quantitative market research to guide investments and strategy

Identify and embed AI, automation, and advanced analytics to improve insight speed, quality, and explainability

Champion robust model governance, documentation, and responsible AI practices to enable auditability and risk management

Requisitos principales Bachelor's degree required; advanced degree preferred (MBA, MS, or PhD in a quantitative, scientific, or life-sciences discipline)

6+ years of relevant pharma, biotech, or consulting experience in forecasting, early-stage pipeline strategy, or market insights

Strong scientific and business acumen

Scientific agility to adapt to new indications, modalities, and targets

Proficiency with NPV, risk-adjusted forecasting, scenarios, and sensitivity analyses for investment cases

Understanding of key commercial drivers, market access, pricing, reimbursement, and US/integral policy factors

Clear, concise communication of complex data to senior stakeholders and governance bodies

Ability to build trust and alignment across global and US stakeholders

Strategic thinking

Cross-functional collaboration

Executive-level storytelling

NPV and risk-adjusted forecasting

Scenario planning and sensitivity analysis

AI/ML concepts and automation in analytics

📌 Global Insights & Forecasting Director - Early Assets & Business Development, R&I (Barcelona)
🏢 AstraZeneca
📍 Barcelona